PATHOGENETIC MECHANISMS UNDERLYING THE DEVELOPMENT OF OSTEOATHROSIS AND THEIR CORRECTION PROCEDURES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Degenerative-dystrophic diseases of the joints and vertebral column rank first in the prevalence of locomotor system diseases. The paper considers approaches to the pathogenetic therapy for osteoarthritis using the well tested drugs that have been proven safe when used for a long time.

Full Text

Restricted Access

About the authors

A. Maryanovsky

Email: docaam@yandex.ru
Professor MD N.I. Pirogov Russian National Research Medical University Moscow

References

  1. Lozada C., del Rio E., Reitberg D. et al. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee // Arthritis Rheumatol. - 2014; 66 (suppl.): S1266.
  2. Lesiak A., Gottwald R., Weiser M. Skutecznosc kuracji preparatem Zeel T w iniekcjach dostawowych okolostawowych i domiesniowych w chorobie zwyrodnieniowej stawow // Medycyna Biologiczna. - 2001; 2: 30-6.
  3. Gottwald R., Weiser M. Treatment of osteoarthritis of the knee with Zeel T // Medicina Biolögica. - 2000; 13 (4): 109-13.
  4. Wodick R., Steininger K., Zenner S. The biological treatment of articular affections - results of a study conducted with 498 patients // Biologische Medizin. - 1993; 3: 127-35.
  5. Hieber F. Intra-articular treatment of osteoarthritis and post-traumatic arthralgia with Zeel // Fortschritte der Medizin. - 1971; 89 (18): 778-80.
  6. Jäggi R., Würgler U., Grandjean F. et al. Dual inhibition of 5-lipoxygenase/ cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability // Inflamm. Res. - 2004; 53 (4): 150-7.
  7. Birnesser H., Stolt P. The homeopathic preparation Zeel comp. N: A review of the molecular and clinical data // Explore (NY). - 2007; 3 (1): 16-22.
  8. Tunon H., Olavsdotter C., Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis // J. Ethnopharmacol. - 1995; 48: 61-76.
  9. Basini G., Santini S., Bussolati S. et al. Sanguinarine inhibits VEGF-induced Akt phosphorylation // Ann. N. Y. Acad. Sci. - 2007; 1095: 371-6.
  10. Basini G., Bussolati S., Santini S. et al. Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix // Biofactors. - 2007; 29 (1): 11-8.
  11. Schmolz M. Transforming Growth Factor beta (TGF-ß): eine neue Regelstrecke für antiphlogistische Therapien? // Biol. Med. - 2000; 29 (1): 31-4.
  12. Schmolz M., Heine H. Homöopathische Substanzen aus der antihomotoxischen Medizin modulieren die Synthese von TGF-ß1 in menschlichen Vollblutkulturen // Biol. Med. - 2001; 30 (2): 61-5.
  13. Stancikova M., Bély M., Svik K. et al. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee // Rheumatologia. - 1999; 13 (3): 101-8.
  14. Weh L., Fröschle G. Incubation in preparations as a means of influencing cartilage mechanics: a mechanical study // Biol. Therapy. - 1990; 8 (4): 91-3.
  15. Haseeb A., Haggi T. Immunopathogenesis of osteoarthritis // Clin. Immunol. - 2013; 146 (3): 185-96.
  16. Bonnet C., Walsh D. Osteoarthritis, angiogenesis and inflammation // Rheumatology. - 2005; 44: 7-16.
  17. Malemud C. Anti-cytokine therapy for osteoarthritis // Drugs Aging. - 2010; 27 (2): 95-115.
  18. Fernadendes J., Materl-Pelletier J., Pelletier J. The role of cytokines in osteoarthritis pathophysiology // Biorheology. - 2002; 39 (1-2): 237-46.
  19. Pearle A., Scanzello C., George S. et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis // Osteoarthritis Cartilage. - 2007; 15 (5): 516-23.
  20. Walsh D., Pearson C. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases // Arthritis Res. - 2001; 3: 147-52.
  21. Mentlein R., Pufe T. New functions of angiogenic peptides in osteoarthritic cartilage // Curr. Rheumatol. Rev. - 2005; 1: 37-45.
  22. Vane J., Botting R. Anti-inflammatory drugs and their mechanism of action // Inflamm. Res. - 1998; 47 (Suppl. 2): 78-87.
  23. Park J., Pillinger M., Abramson S. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases // Clin. Immunol. - 2006; 119 (3): 229-40.
  24. Giuliano F., Warner T. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems // J. Pharmacol. Exp. Ther. - 2002; 303 (3): 1001-6.
  25. Kawabata A. Prostaglandin E2 and pain - an update // Biol. Pharm. Bull. -2011; 34 (8): 1170-3.
  26. Adatia A., Rainsford K., Kean W. Osteoarthritis of the knee and hip. Part I: aetiology and pathogenesis as a basis for pharmacotherapy // J. Pharm. Pharmacol. - 2012; 64 (5): 617-25.
  27. Pountos I., Georgouli T., Bird H. et al. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications and side-effects // IJICMR. - 2011; 3: 19-27.
  28. Heller A., Koch T. et al. Lipid mediators in inflammatory disorders // Drugs. - 1998; 55 (4): 487-96.
  29. Leone S., Ottani A., Bertolini A. Dual acting anti-inflammatory drugs // Curr. Top Med. Chem. - 2007; 7 (3): 265-75.
  30. Espanha M. Articular cartilage: structure and histochemical composition // Acta Reumatol. Port. - 2010; 35 (5): 424-33.
  31. Martel-Pelletier J., Boileau C., Pelletier J. et al. Cartilage in normal and osteoarthritis conditions // Best Pract. Res. Clin. Rheumatol. - 2008; 22 (2): 351-84.
  32. Aigner T., Soeder S., Haag J. IL-1 ß and BMPs - interactive players of cartilage matrix degradation and regeneration // Eur. Cell. Mater. - 2006; 12: 49-56.
  33. Yasuda T., Poole A. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway // Arthritis Rheum. - 2002; 46: 138-48.
  34. Lozada C., del Rio E., Reitberg D. et al. Risk-benefit of co-administerd Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK) // Ann. Rheum. Dis. - 2015; 74 (Suppl. 2): Abstract THU0441.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies